What is the difference between ACITRETIN and Risankizumab?

ACITRETIN is a Retinoid and Risankizumab is a Biologic (IL-23 Inhibitor). They reach a similar treatment goal through different pharmacological mechanisms, which is why one may be tolerated by a patient who could not tolerate the other.

Is ACITRETIN the same as Skyrizi?

No. ACITRETIN (ACITRETIN) and Skyrizi (Risankizumab) are distinct medications. They are sometimes confused because of similar branding or because they treat overlapping conditions, but they have different active ingredients and different safety profiles.

Which has fewer side effects, ACITRETIN or Risankizumab?

Side-effect frequency varies by individual. The side-effect comparison section on this page shows FAERS-reported events for each drug side by side. FAERS is voluntary reporting, so it reflects what patients and clinicians chose to report, not absolute population risk.

Can I switch from ACITRETIN to Risankizumab?

Switching medications should always be done under prescriber supervision. The "patient stories" section on this page includes accounts from people who have made the switch and what their transition felt like, but those are individual experiences, not protocols.

ACITRETIN vs Risankizumab

Compare ACITRETIN (ACITRETIN) and Risankizumab (Skyrizi) — clinical data, side effects, and patient experiences.

ACITRETIN

ACITRETIN · Retinoid

How it works

Other agent

Approved for

INDICATIONS AND USAGE Acitretin Capsules

USP are indicated for the treatment of severe psoriasis in adults. Because of significant adverse effects associated with its use

Acitretin Capsules

USP should be prescribed only by those knowledgeable in the systemic use of retinoids. In females of reproductive potential

OralTablet

Risankizumab

Skyrizi · Biologic (IL-23 Inhibitor)

How it works

Humanized monoclonal antibody that selectively binds to the p19 subunit of IL-23, inhibiting IL-23-dependent inflammatory signalling.

Approved for

Plaque Psoriasis

Psoriatic Arthritis

Crohn's Disease

FDA: 2019SubcutaneousInjection

Quick Comparison

ACITRETINRisankizumab

Drug Class

Retinoid

Biologic (IL-23 Inhibitor)

Route

Oral

Subcutaneous

Half-Life

—

FDA Approved

—

2019

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

ACITRETIN

Drug Not Working

>10%

Fatigue

1-10%

Itching

1-10%

Nausea

1-10%

Headache

0.1-1%

Fever

0.1-1%

General Unwellness

0.1-1%

Diarrhea

0.1-1%

Risankizumab

Drug Not Working

1-10%

Fatigue

1-10%

Joint Pain

1-10%

Itching

1-10%

Falls

1-10%

Headache

0.1-1%

Diarrhea

0.1-1%

Rash

0.1-1%

FDA Warnings

ACITRETIN

CONTRAINDICATIONS AND WARNINGS: Pregnancy Acitretin must not be used by females who are pregnant, or who intend to become pregnant during therapy or at any time for at least 3 years following discontinuation of therapy
Acitretin should be prescribed only by those who have special competence in the diagnosis and treatment of severe psoriasis, are experienced in the use of systemic retinoids, and understand the risk of teratogenicity
, P regnancy P revention is E ssential with T reatment, has been developed to educate women of childbearing potential and their healthcare providers about the serious risks associated with acitretin and to help prevent pregnancies from occurring with the use of this drug and for 3 years after its discontinuation
Acitretin is contraindicated in females of reproductive potential unless the patient meets ALL of the following conditions : Must have had 2 negative urine or serum pregnancy tests with a sensitivity of at least 25 mIU per mL before receiving the initial prescription for acitretin

Risankizumab

Infections
Avoid live vaccines

Clinical Trial Data

No head-to-head clinical studies found for ACITRETIN vs Risankizumab.

ACITRETIN vs Risankizumab: What You Should Know

Key Differences

ACITRETIN is a Retinoid, while Risankizumab belongs to the Biologic (IL-23 Inhibitor) class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles. ACITRETIN is administered via Oral, whereas Risankizumab uses Subcutaneous. Route of administration can affect onset of action and patient adherence.

Safety Considerations

ACITRETIN carries 4 FDA warnings. Risankizumab carries 2 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

ACITRETIN vs ISOTRETINOIN→ACITRETIN vs ALITRETINOIN→ACITRETIN vs TRETINOIN→ACITRETIN vs CLINDAMYCIN PHOSPHATE AND TRETINOIN GEL 1.2%→ACITRETIN vs TRETINOIN AND BENZOYL PEROXIDE→ACITRETIN vs CLINDAMYCIN PHOSPHATE AND TRETINOIN→

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

ACITRETIN: DailyMed label · FAERS adverse events · ClinicalTrials.gov
Risankizumab: DailyMed label · FAERS adverse events · ClinicalTrials.gov

Loading comparison data...

ACITRETIN vs Risankizumab

Compare ACITRETIN (ACITRETIN) and Risankizumab (Skyrizi) — clinical data, side effects, and patient experiences.

ACITRETIN

ACITRETIN · Retinoid

How it works

Other agent

Approved for

INDICATIONS AND USAGE Acitretin Capsules

USP are indicated for the treatment of severe psoriasis in adults. Because of significant adverse effects associated with its use

Acitretin Capsules

USP should be prescribed only by those knowledgeable in the systemic use of retinoids. In females of reproductive potential

OralTablet

Risankizumab

Skyrizi · Biologic (IL-23 Inhibitor)

How it works

Humanized monoclonal antibody that selectively binds to the p19 subunit of IL-23, inhibiting IL-23-dependent inflammatory signalling.

Approved for

Plaque Psoriasis

Psoriatic Arthritis

Crohn's Disease

FDA: 2019SubcutaneousInjection

Quick Comparison

ACITRETINRisankizumab

Drug Class

Retinoid

Biologic (IL-23 Inhibitor)

Route

Oral

Subcutaneous

Half-Life

—

FDA Approved

—

2019

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

ACITRETIN

Drug Not Working

>10%

Fatigue

1-10%

Itching

1-10%

Nausea

1-10%

Headache

0.1-1%

Fever

0.1-1%

General Unwellness

0.1-1%

Diarrhea

0.1-1%

Risankizumab

Drug Not Working

1-10%

Fatigue

1-10%

Joint Pain

1-10%

Itching

1-10%

Falls

1-10%

Headache

0.1-1%

Diarrhea

0.1-1%

Rash

0.1-1%

FDA Warnings

ACITRETIN

CONTRAINDICATIONS AND WARNINGS: Pregnancy Acitretin must not be used by females who are pregnant, or who intend to become pregnant during therapy or at any time for at least 3 years following discontinuation of therapy
Acitretin should be prescribed only by those who have special competence in the diagnosis and treatment of severe psoriasis, are experienced in the use of systemic retinoids, and understand the risk of teratogenicity
, P regnancy P revention is E ssential with T reatment, has been developed to educate women of childbearing potential and their healthcare providers about the serious risks associated with acitretin and to help prevent pregnancies from occurring with the use of this drug and for 3 years after its discontinuation
Acitretin is contraindicated in females of reproductive potential unless the patient meets ALL of the following conditions : Must have had 2 negative urine or serum pregnancy tests with a sensitivity of at least 25 mIU per mL before receiving the initial prescription for acitretin

Risankizumab

Infections
Avoid live vaccines

Clinical Trial Data

No head-to-head clinical studies found for ACITRETIN vs Risankizumab.

ACITRETIN vs Risankizumab: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.